Suscribirse

Current hyperkalemia interventions co-administered with a dextrose 10% solution significantly lower hypoglycemic rates (CHICA-D10) - 10/09/24

Doi : 10.1016/j.ajem.2024.07.061 
Francisco Ibarra, PharmD, BCCCP a, b, c, ⁎ , Cade Fountain b , Tyler Fallert a
a Community Regional Medical Center, Department of Pharmacy Services, P.O. Box 1232, Fresno, CA 93715, United States of America 
b California Health Sciences University (CHSU), College of Osteopathic Medicine, 2500 Alluvial Ave, Clovis, CA 93611, United States of America 
c University of California San Francisco at Fresno, Department of Emergency Medicine, 155 N Fresno St, Fresno, CA 93701, United States of America 

⁎Corresponding author at: Community Regional Medical Center, Department of Pharmacy Services, P.O. Box 1232, Fresno, CA 93715, United States of America.Community Regional Medical CenterDepartment of Pharmacy ServicesP.O. Box 1232FresnoCA93715United States of America

Abstract

Background

Current protocols which include the administration of a single dextrose dose concomitantly with insulin are inadequate as hypoglycemia commonly occurs 60 min after insulin administration and may persist for up to two hours post-insulin administration. To prevent delayed hypoglycemic events, our institution revised our adult acute hyperkalemia order set to include hypoglycemic preventative measures not currently described in the literature.

Methods

The primary purpose of this retrospective study was to determine if the new adult acute hyperkalemia order set resulted in lower rates of hypoglycemia (glucose <70 mg/dL) compared to the old order set in patients with impaired renal clearance and lower pre-insulin glucose values. In addition to reducing the IV regular insulin dose from 10 to 5 units, the new order set recommends patients receive a 250 mL dextrose 10% solution over two hours in addition to a 50 mL dextrose 50% IV push concomitantly with IV regular insulin if their pre-insulin glucose is ≤250 mg/dL. Patients were included if they were adults, received IV regular insulin from the order set within six hours of presenting to the ED, had a pre-insulin potassium >5.5 mmol/L, had a pre-insulin glucose ≤250 mg/dL, and had impaired renal clearance [creatinine clearance (CrCl) < 30 mL/min or dialysis dependent].

Results

100 patients were included in each arm. The median pre-insulin potassium levels were 6.4 mmol/L and 6.3 mmol/L in the old and new groups, respectively (p = 0.133). The median pre-insulin glucose levels were 120 mg/dL and 107.5 mg/dL in the old and new groups, respectively (p = 0.013). Twenty (20%) patients in the old group developed hypoglycemia, whereas six (6%) patients in the new group developed hypoglycemia (p = 0.003). There was no significant difference between the two groups in number of patients who achieved a post-insulin potassium level ≤ 5.5 mmol/L.

Conclusion

Our study found that our approach of additionally administering a 250 mL dextrose 10% solution upon therapy initiation is associated with significantly lower rates of hypoglycemia. Our findings indicate that hypoglycemia rates can be significantly reduced in vulnerable populations if additional preventative measures are employed.

El texto completo de este artículo está disponible en PDF.

Keywords : Hyperkalemia, Hypoglycemia, Renal failure, Potassium, Insulin


Esquema


© 2024  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 84

P. 120-123 - octobre 2024 Regresar al número
Artículo precedente Artículo precedente
  • A dynamic online nomogram predicting post-traumatic arrhythmias: A retrospective cohort study
  • Jianmei Long, Xiaohui Liu, Shasha Li, Cui Yang, Li Li, Tianxi Zhang, Rujun Hu
| Artículo siguiente Artículo siguiente
  • The impact of recreational cannabis legalization on ED visit rates for acute cannabis intoxication
  • An Nguyen, Ray Lee, Lili Zhao, Lihua Qu, Brett Todd

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.